with anti-MAD2 and anti-WT1 antibodies, which revealed a significant co-localization pattern during the pro-metaphase of mitosis (Fig. 2c). The centromeric localization of MAD2 and WT1 was also ...

Samples were incubated overnight at 4 °C with antibodies to Wt1 (1:800; C19, Santa Cruz Biotechnology) or GFP (1:800; Abcam) diluted with 0.1% BSA and 0.3% Triton X-100 in PBS (pH 7.4), followed ...

In just one year since the start of the collaboration, the companies have identified a WT1/HLA-A02-specific T cell engager (WT1xCD3x4-1BB tri-specific antibody) with outstanding preclinical anti ...

"This is a new approach for attacking WT1, an important cancer target, with an antibody therapy. This is something that was previously not possible," said David A. Scheinberg, MD, PhD, Chair of ...

"This is a new approach for attacking WT1, an important cancer target, with an antibody therapy. This is something that was previously not possible," said David A. Scheinberg, MD, PhD, Chair of ...

In recent years, however, it has become clear that WT1 can also act as an oncogene in several paediatric and adult cancers. Indeed, WT1 antibody therapies are showing promise in clinical trials for ...

In the new study, a monoclonal antibody, called ESK1, targets a protein associated with many types of cancer. The targeted protein, called WT1, is over-produced in a range of leukemias and other ...

Early results of a trial to treat leukaemia with a WT1 DNA vaccine, has shown robust vaccine-specific antibody responses in all vaccinated patients evaluated to date. Furthermore, T cell immune ...

Early results of a trial to treat leukemia with a WT1 DNA vaccine, has shown robust vaccine-specific antibody responses in all vaccinated patients evaluated to date. Furthermore, T cell immune ...

Unlike other human therapeutic monoclonal antibodies, which can only target proteins that remain on the outside of cancer cells, ESK1 targets WT1, a protein that resides on the inside of the cell.